Intriguingly, we found that the half-life of SRC-3 was significantly extended in BR myeloma cells (Fig. 4e, Fig. S4a); this finding was similar to what was observed in their parental cells with ectopic overexpression of NSD2 (Fig. S4b, Fig. 4f, Fig. S4c), and this protection occurred in a dose-dependent manner (Fig. S4d). The gene discussed is NSD2; the disease is plasma cell myeloma.